Table 1

Patient characteristics and sIL-2R measurements
controls all patients stage of cirrhosis
no cirrh. Child A Child B Child C
n 41 71 23 21 13 14
sex male/ female n 20/21 37/34 11/12 8/13 8/5 10/4
age yrs 35 54 43 61 63 53
median (range) (18–65) (17–74) (17–64) (30–74) (28–74) (34–73)
disease etiology n n.a.
 virus hepatitis 24 11 8 5 0
 biliary/autoimmune 8 2 4 1 1
 alcohol 21 3 5 3 10
 other origin 18 7 4 4 3
MELD score n.a. n.a. n.a. 8 11 17
median (range) (6–17) (7–16) (12–28)
ALT U/L 19 41 64 34 36 29
median (range) (5–54) (7–568) (15–568) (8–188) (7–92) (14–261)
bilirubin mg/dL n.a. 1.3 0.7 0.9 1.6 5.1
median (range) (0.2-12.5) (0.4-8.7) (0.2-8.9) (0.2-9.0) (1.8-12.5)
albumin mg/dL n.a. 38 45 40 27 27
median (range) (12–50) (40–50) (30–43) (12–38) (22–31)
international normalized n.a. 1.07 0.98 1.06 1.20 1.43
ratio median (range) (0.92-1.69) (0.93-1.12) (0.92-1.32) (0.99-1.39) (1.18-1.69)
hyaluronic acid μg/l n.a. 190 28 205 305 800
median (range) (10–800) (10–210) (36–800) (140–800) (190–800)
procollagen-III-peptide 584 1135 973 990 1710 2500
median (range) μg/l (157–1160) (470–6560) (470–1750) (589–1930) (639–2630) (1010–6560)
creatinine mg/dL 0.7 0.7 0.7 0.7 0.6 0.8
median (range) (0.6-0.9) (0.3-2.4) (0.4-1.0) (0.4-1.9) (0.4-1.8) (0.3-2.4)
cystatin C mg/L n.a. 0.98 0.80 1.01 1.20 1.46
median (range) (0.40-2.81) (0.40-1.16) (0.69-2.81) (0.74-2.78) (0.80-2.41)
GFR [cyst. C] ml/min n.a. 88 123 83 64 45
median (range) (15–395) (66–395) (15–158) (15–140) (19–123)
total monocytes x106/L 416 490 419 426 477 816
median (range) (165–852) (70–2208) (70–860) (296–1332) (162–2208) (294–1180)
CD14++CD16- monocytes 386 442 384 387 425 714
x106/L median (range) (155–748) (65–2101) (65–807) (250–1155) (142–2101) (257–1089)
CD14+CD16+ monocytes 32.4 46 40 45 67 92
x106/L median (range) (10–108) (4.6-175) (4.6-158) (26–175) (18–135) (6.4-153)
sIL-2R kU/L 444 818 374 764 1101 1029
median (range) (14–1193) (39–3976) (204–1795) (39–3976) (317–2494) (370–3350)

ALT, alanine aminotransferase activity; GFR, glomerular filtration rate; MELD, model of end-stage liver disease; n.a., not applicable / not assessed; sIL-2R, soluble interleukin-2 receptor.

Seidler et al.

Seidler et al. BMC Gastroenterology 2012 12:38   doi:10.1186/1471-230X-12-38

Open Data